Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

Neurology
Nicolas Phielipp
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
Parkinson Disease

Study Description

Participants will undergo a surgical implantation of cells that will mature into dopamine-producing neurons under general anesthesia into a part of the brain where dopamine production is decreased in patients with Parkinson Disease. The effect on Parkinson Disease symptoms, safety and tolerability, and cell survival are assessed for 5 years post-transplant (with MRI and PET imaging scans of the brain). Safety and tolerability are assessed annually for an additional 10 years via telephone call (total follow-up of 15 years)

Eligibility

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.